Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...

The complement system, a pivotal element of antiviral immunity, is a cascade of proteins found in the bloodstream and at mucosal sites, such as the respiratory tract. Activated through three different ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

“Our findings highlight menopause as a critical turning point for women’s immunity. While ageing affects everyone, the loss ...